Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-0.90
EPS est.
$-1.27
EPS surprise
+29.30%
1-day move
+3.16%
Ultragenyx's better-than-expected EPS indicates improved cost management or operational efficiency. However, the lack of revenue data leaves some uncertainty about overall performance. The stock's 3.16% increase suggests that investors reacted positively to the EPS surprise, indicating confidence in the company's future prospects despite the absence of revenue details.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.90 | $-1.00 | +29.30% |
| Revenue | — | $183M | — |
No transcript is on record, and the analysis is based on numerical results only.
Ultragenyx Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases. With a market cap of $3 billion, it plays a crucial role in addressing unmet medical needs in the healthcare sector.
Last quarter
In Q1-2026, Ultragenyx reported an EPS of $-1.84, missing estimates by nearly 19%. The stock saw a slight increase of 0.81% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-5.22%
Avg 1-day reaction
-0.80%
Analysts are cautiously optimistic about Ultragenyx's upcoming earnings, with expectations of a narrower EPS loss and steady revenue growth.
Bull case
If the company can exceed revenue expectations and show signs of improved clinical trial results, it could lead to a positive market reaction.
Bear case
Conversely, if the company fails to meet revenue targets or provides disappointing updates on its drug pipeline, it may face significant downward pressure.
Key metrics to watch
EPS
$-1.00Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$183MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Ultragenyx's revenue meet or exceed the consensus estimate of $183 million?
Revenue performance is critical for assessing the company's market traction and growth potential.
Q2
What updates will management provide on the progress of key clinical trials?
Investors will closely watch for any developments that could impact future product launches and revenue streams.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may underestimate the potential for Ultragenyx to surprise on revenue, given recent advancements in their clinical pipeline.
Supporting evidence
The company has a history of surprising on revenue, as seen in Q2-2025 when they beat estimates.
Options pricing suggests a significant move, indicating that traders expect volatility that could favor a positive outcome.
Key risk
If revenue comes in above $195 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to deliver on revenue expectations and clinical advancements.
Bull confirmed if
Revenue exceeding $183 million and positive updates on clinical trials would confirm the bull case.
Bear confirmed if
Revenue falling below $171 million or negative trial updates would support the bear case.
What the market is pricing for the move.
Implied Move
±32.37%
Historical Avg
±2.8%
The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.
Options are pricing ±32.4% while RARE has averaged ±2.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
38.5%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
112.49%
of float
Insider
3.44%
of float
Holders
434
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
10,654,276 sh · $158.6M
10.81%
46.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Ultragenyx beats expectations, history suggests a potential stock increase of around +0.63%, confirming positive market sentiment.
In line / cautious
A cautious inline report could lead to a muted response as investors await further clarity on future growth.
Miss
If the company misses expectations, history suggests a potential decline of about -2.68%, reflecting disappointment in performance.
The lines on the call that would change the story.
RTW Investments LP
7,796,895 sh · $116.1M
7.91%
113.7%
Vanguard Portfolio Management LLC
6,790,135 sh · $101.1M
6.89%
26.1%
AQR Capital Management, LLC
6,560,809 sh · $97.7M
6.65%
43.3%
State Street Corporation
6,158,766 sh · $91.7M
6.25%
22.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.